FocalTherics (NASDAQ:FOCL) Stock Now Rated “Hold” by Sell-Side Analysts

Shares of FocalTherics (NASDAQ:FOCL) have earned a consensus recommendation of “Hold” from the five research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $7.75.

A number of research firms have recently weighed in on FOCL. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a research note on Monday, August 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a research note on Tuesday, August 25th. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price objective on shares of FocalTherics in a report on Friday, August 14th. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th.

Insider Buying and Selling

In other news, Director David Horn purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $47,500. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Lance Willsey acquired 50,000 shares of FocalTherics stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, for a total transaction of $237,500.00. Following the purchase, the director directly owned 1,291,780 shares in the company, valued at $6,135,955. The trade was a 4.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 116,000 shares of company stock worth $551,000 over the last quarter. Insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On FocalTherics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rock Springs Capital Management LP increased its position in shares of FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after buying an additional 91,500 shares in the last quarter. Lido Advisors LLC bought a new position in FocalTherics during the first quarter worth about $40,000. SmartHarvest Portfolios LLC bought a new position in FocalTherics during the first quarter worth about $38,000. Finally, Flax Pond Capital LLC acquired a new position in FocalTherics in the fourth quarter valued at about $2,623,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

FocalTherics Price Performance

Shares of NASDAQ FOCL opened at $4.20 on Friday. The firm has a 50 day simple moving average of $4.76. FocalTherics has a fifty-two week low of $1.75 and a fifty-two week high of $6.40. The firm has a market capitalization of $157.63 million, a price-to-earnings ratio of -4.08 and a beta of -0.06. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 1.38.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The business had revenue of $13.20 million for the quarter. Sell-side analysts expect that FocalTherics will post -0.82 EPS for the current fiscal year.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.